Search hospitals > Florida > Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Claim this profileMiami, Florida 33136
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Cystic Tumor
Conducts research for Lymphoma
Conducts research for Adult T-Cell Leukemia/Lymphoma
793 reported clinical trials
85 medical researchers
Summary
University of Miami Miller School of Medicine-Sylvester Cancer Center is a medical facility located in Miami, Florida. This center is recognized for care of Parotid Gland Cancer, Cancer, Cystic Tumor, Lymphoma, Adult T-Cell Leukemia/Lymphoma and other specialties. University of Miami Miller School of Medicine-Sylvester Cancer Center is involved with conducting 793 clinical trials across 825 conditions. There are 85 research doctors associated with this hospital, such as Julio C Barredo, MD, Jose Lutzky, MD, Chukwuemeka (Emeka) V. Ikpeazu, and Macarena I. De La Fuente.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Julio C Barredo, MDUniversity of Miami Miller School of Medicine-Sylvester Cancer Center8 years of reported clinical research
Expert in Cystic Tumor
Expert in Neuroblastoma
46 reported clinical trials
98 drugs studied
Jose Lutzky, MDUniversity of Miami4 years of reported clinical research
Expert in Melanoma
Studies Skin Cancer
20 reported clinical trials
40 drugs studied
Chukwuemeka (Emeka) V. IkpeazuUniversity of Miami Miller School of Medicine-Sylvester Cancer Center2 years of reported clinical research
Studies Parotid Gland Cancer
Studies Cancer
13 reported clinical trials
34 drugs studied
Macarena I. De La FuenteUniversity of Miami Miller School of Medicine-Sylvester Cancer Center6 years of reported clinical research
Studies Brain Tumor
Studies Solid Tumors
12 reported clinical trials
27 drugs studied
Clinical Trials running at University of Miami Miller School of Medicine-Sylvester Cancer Center
Lung Cancer
Esophageal Adenocarcinoma
Esophageal Carcinoma
Skin Cancer
Parotid Gland Cancer
Cancer
Gastroesophageal Junction Adenocarcinoma
Ovarian Cancer
Brain Tumor
Pancreatic Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Miami Miller School of Medicine-Sylvester Cancer Center?
Where is University of Miami Miller School of Medicine-Sylvester Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Miami Miller School of Medicine-Sylvester Cancer Center accept?
What awards or recognition has University of Miami Miller School of Medicine-Sylvester Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.